Free Daily Podcast Summary
The Top Line: Daily Summaries Delivered
by Fierce Life Sciences
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago15 min
GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing
In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the growing role of point-of-care advertising in pharmaceutical marketing. First, we look at GSK's big week, which included FDA approval for Jemperli in certain patients with rectal cancer, offering the possibility of avoiding chemotherapy, radiation and surgery. The company also secured a landmark approval for Hibsago, a chronic hepatitis B treatment that could deliver a functional cure for some patients. We also discuss Roche's expanded partnership with China's Hansoh Pharmaceutical, an antibody-drug conjugate deal featuring up to $15 billion in potential milestone payments. Then, Fierce Pharma's Zoey Becker sits down with Nicole Divinagracia, president of the Point of Care Marketing Association, to discuss the rapid growth of point-of-care advertising. Divinagracia explains what's driving that momentum, how the channel is evolving and why marketers should incorporate point of care earlier in their planning. They also explore efforts to establish more consistent measurement standards and best practices for reaching patients and healthcare professionals at critical moments in the care journey. To learn more about the topics in this episode: GSK’s Jemperli scores FDA approval in rectal cancer, backed by high complete response rate GSK brings promise of 'functional cure' to hepatitis B finish line with FDA nod for Hibsago Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact Point-of-care pharma marketing spending passes $1B milestone See omnystudio.com/listener for privacy information.
- 2 weeks ago25 min
Inside Teva's Weltruza launch and Novo's GLP-1 strategy
In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new opportunities in the pharmaceutical industry. From Teva's growing portfolio of innovative medicines to Novo's expanding reach in the GLP-1 market, both companies are looking to build on their momentum as they prepare for the next phase of growth. First, Fierce Pharma's Fraiser Kansteiner speaks with Christine Fox, Teva's executive vice president of U.S. commercial and head of its innovative medicines franchise, and Eric Hughes, M.D., Ph.D., executive vice president of global R&D and chief medical officer. They discuss the FDA's recent approval of Weltruza, a once-monthly injectable treatment for schizophrenia, lessons learned from the company's earlier rollout of Uzedy and how its growing portfolio of innovative medicines fits into its broader strategy. They also explain how Weltruza's formulation could help address unmet needs in schizophrenia treatment. Then, we turn to Novo and the expanding market for GLP-1 drugs. At Fierce Pharma Week in Philadelphia, Fierce Pharma's Zoey Becker sat down with Kevin Donahoe, Novo's vice president and head of diabetes therapy area marketing and patient solutions, to discuss how the popularity of GLP-1s is creating new opportunities to reach and educate patients. Their conversation covers Novo's evolving marketing strategy, lessons from the Wegovy pill launch and the company's outlook on the future of obesity treatment as more medicines enter the market. To learn more about the topics in this episode: Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorpho… No more Nordisk as Novo goes it alone amid rebranding push The Oral GLP-1 Tracker: Prescriptions edge down for Novo, Lilly How drugmakers are tapping into the GLP-1 frenzy's unprecedented 'consumer overlay' See omnystudio.com/listener for privacy information.
- 2 weeks ago32 min
[Sponsored] The Next Chapter for AI in Clinical Trials
Clinical AI is moving from systems that predict and summarize toward agents that can help execute parts of a workflow. In this sponsored episode of The Top Line, Will Hurth speaks with Saama’s Ari Srinivasan, chief customer success and growth officer, and Yatesh Midha, associate vice president of product management, about what that evolution could mean for clinical development. The conversation places Agent OS, Saama’s orchestration and governance layer, within a broader shift from disconnected AI tools to coordinated clinical workflows. A practical example explores how an agentic data manager could support SAE reconciliation by retrieving records from EDC and safety systems, comparing fields and presenting important mismatches with supporting evidence. The interview also considers what trusted use requires in a regulated environment: task-appropriate models, grounding, provenance, permission controls, transparency, auditability and human oversight. The central argument is not that agents replace clinical experts, but that they take on repetitive information-gathering and comparison work so experts can focus on complex cases and consequential decisions. Listen to the full interview to learn more about the role governed, connected agents could play in the next phase of AI-enabled trials.See omnystudio.com/listener for privacy information.
- 3 weeks ago22 min
How AI could improve clinical trial decision-making (Sponsored)
What if clinical development teams could evaluate potential trial outcomes before a study reaches patients? In this sponsored episode of The Top Line, host Irena Luo speaks with Raja Shankar, vice president for machine learning within AI and technology solutions at IQVIA, about a foundation model designed specifically for life sciences. Shankar explains why general-purpose models may overlook important relationships in patient and clinical trial data and how post-training on life sciences data can make AI more relevant to predictive decision-making. He explores how the model represents patients, diseases, treatments and endpoints, then applies those relationships to anticipate events across a patient journey. The conversation also examines the strategic role of study simulation, including how teams can compare scenarios, challenge assumptions and refine protocol decisions before a trial begins. Shankar addresses the evidence, transparency and expert oversight needed to build confidence in model outputs. Listen to the podcast to learn how simulation could help reduce uncertainty and improve clinical development planning.See omnystudio.com/listener for privacy information.
- 3 weeks ago23 min
How we picked the Fierce 15
What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector.In this week’s episode of "The Top Line," the Fierce Biotech editorial team reflects on the process of distilling more than 150 high-quality entries into the final Fierce 15 list. The team discusses how the ambitions of these companies are higher than ever and looks back on some of its conversations with the winners, covering everything from cutting-edge antibody research and novel fertility treatments to innovative ways to source radioisotopes. To learn more about the topics in this episode: Introducing Fierce Biotech's 2026 Fierce 15 Regeneron backs $75M series A for antibody upstart Infinimmune Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy Fierce Biotech at London Life Sciences Week: Learn more and register Learn more about the Fierce Vanguard Awards Gala See omnystudio.com/listener for privacy information.
- Oct 2, 202618 min
Locking in on pharma’s consumerization trend
With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern-hair-loss biotech is eyeing opportunities in an evolving market that could expand well beyond his own company. In this week’s episode of "The Top Line," Fierce’s Fraiser Kansteiner chats with Reid Waldman, co-founder and CEO of hair loss-focused biotech Veradermics. With impressive data on its reformulated minoxidil candidate and an upsized IPO earlier this year, Veradermics has generated significant interest in its approach. The company now hopes to tap into an increasingly consumer-minded market for certain drugs, a shift Waldman says could carry over to a range of indications and products. To learn more about the topics in this episode: A cut above: Veradermics locks in $256M IPO and shares spike Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of… ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordi… See omnystudio.com/listener for privacy information.
- Sep 25, 202624 min
Fierce Pharma Week: A look at the biggest trends, campaigns and conversations
Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and communications. In this episode of "The Top Line," Fierce editors share the conversations, trends and moments that stood out from the event. Topics include Genentech’s use of humor and celebrity storytelling to raise awareness of diabetic macular edema, how Novo is navigating the extraordinary attention around GLP-1 drugs, and the growing role of AI in pharma marketing. The team also looks at some of the campaigns honored at the Fierce Pharma Marketing Awards and the creative approaches companies are using to reach patients and healthcare professionals. To learn more about the topics in this episode: ‘People like the sincerity of it’: comedian Damon Wayans on humor, relatability and DME awareness in… Standout pharma marketing takes the stage at the 2026 Fierce Pharma Marketing Awards Panthers and zebras and meerkats, oh my: A peek behind the curtain at Fierce Pharma Week 2026 Former 'Real Housewives' star Jenn Fessler and CineHealth’s Tracey Yaw break down authentic healthca… 'The growth driver of our organization'; Genentech CMO Zoë Lazarre on experimental marketing, AI and… Journalist and menopause advocate Tamsen Fadal shines a light on overlooked women’s health topics See omnystudio.com/listener for privacy information.
- Sep 18, 202623 min
Inside the growing world of biopharma prediction markets
Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researchers, contractors and others may have access to confidential information that could give them an edge. In this episode of “The Top Line,” Fierce Biotech’s Will Maddox talks with David Oliwenstein, a partner at Pillsbury Winthrop Shaw Pittman and former SEC enforcement attorney, about how regulators may approach misuse of nonpublic information in prediction markets, why biopharma could face heightened scrutiny and what companies should be doing now to reduce their risk. To learn more about the topics in this episode: Betting on biotech: Prediction markets set sights on clinical trials See omnystudio.com/listener for privacy information.
Get The Top Line summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
The AI in Business Podcast
Interviews with AI executives reveal practical applications and strategic insights for business leaders adopting AI.
This Week in AI
Four AI experts analyze the latest news and trends in artificial intelligence each week.
Learn AI
Learn AI
Pioneers of AI
AI experts discuss how artificial intelligence is changing society and shaping the future.
Global News Podcast
Global News Podcast AI
The Intelligence Shift
Industry leaders discuss how AI is transforming fields like sports, film, and healthcare with a Chief AI Officer.
The Anthropic AI Daily Brief
Breaks down Anthropic's latest AI advancements and their real-world implications in clear, accessible language.
AI Breakdown
Explores the latest advancements, ethical issues, and real-world impacts of artificial intelligence across industries.
This Week in Cardiology
A weekly summary and analysis of key developments in cardiology for healthcare professionals.
Sourcery
Interviews with top investors, CEOs, and founders.
Science Weekly
The Guardian provides weekly updates on the latest science and environment news.
The Jaeden Schafer Podcast
Explores technology, startups, and the creator economy with clear analysis on AI, business, and emerging trends.
About The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Top Line in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Top Line daily summary?
It's a free AI-powered email that summarizes new episodes of The Top Line as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Top Line podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Top Line product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Fierce Life Sciences.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does The Top Line release new episodes?
The Top Line publishes 2x weekly. Our AI generates a summary within hours of each new episode.
What topics does The Top Line cover?
The Top Line covers topics including News, Business. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Top Line summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.